Macrogen
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Macrogen reads and decodes genetic material, the DNA sequences of humans, animals, plants, viruses, and bacteria, and delivers the results as a service to researchers, clinicians, and other life-science users worldwide.
It operates genome-analysis centers in major cities across multiple countries, serving a global customer base. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company earns the large majority of its revenue from genomic sequencing services, with smaller contributions from oligonucleotide synthesis, microarray analysis, and genetically modified mouse production.
Summary is AI-generated and may contain errors · figures from DART filings
Macrogen operates its genomic services through a network of genome-center locations in key cities around the world, giving it a direct international service footprint rather than relying solely on domestic operations.
Macrogen in five facts
What does Macrogen do?
Macrogen reads and decodes genetic material, the DNA sequences of humans, animals, plants, viruses, and bacteria, and delivers the results as a service to researchers, clinicians, and other life-science users worldwide.
Where is Macrogen listed and in which sector?
Macrogen (Korean name: 마크로젠) trades under KRX code 038290 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Macrogen?
Its market capitalisation was US$94.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Macrogen's latest annual revenue and operating profit?
For fiscal year 2025, Macrogen reported revenue of US$147.4M, operating profit of US$136.7K and a net loss of US$152.2K, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 43.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 1
- [Amended] Supply contract signed
Macrogen updated a previously disclosed supply contract with Korea Research Institute of Bioscience and Biotechnology, now worth US$13.3M, about 13.54% of its recent annual revenue, running through Dec 2026.
Supply contract · Sep 10 - [Amended] Supply contract signed
Macrogen updated a previously disclosed supply contract with Korea Research Institute of Bioscience and Biotechnology, now worth US$11.6M, about 13.22% of its recent annual revenue, running through Dec 2026.
Supply contract · Mar 27 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Macrogen reported consolidated results for FY2025: revenue of US$136M (+43.8% year on year), operating profit of US$115K (from a loss a year earlier) and a net loss of US$2.34M.
Earnings · Feb 13 - Cash/in-kind dividend decision
Macrogen declared a cash dividend of US$0.35 per share.
Dividend · Feb 13